These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20729640)

  • 1. The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy.
    Wei Y; Kadia T; Tong W; Zhang M; Jia Y; Yang H; Hu Y; Viallet J; O'Brien S; Garcia-Manero G
    Autophagy; 2010 Oct; 6(7):976-8. PubMed ID: 20729640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy.
    Wei Y; Kadia T; Tong W; Zhang M; Jia Y; Yang H; Hu Y; Tambaro FP; Viallet J; O'Brien S; Garcia-Manero G
    Clin Cancer Res; 2010 Aug; 16(15):3923-32. PubMed ID: 20538760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.
    Xargay-Torrent S; López-Guerra M; Saborit-Villarroya I; Rosich L; Campo E; Roué G; Colomer D
    Clin Cancer Res; 2011 Jun; 17(12):3956-68. PubMed ID: 21652541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.
    Miller CP; Rudra S; Keating MJ; Wierda WG; Palladino M; Chandra J
    Blood; 2009 Apr; 113(18):4289-99. PubMed ID: 19182209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting autophagy potentiates the apoptotic effect of histone deacetylase inhibitors in t(8;21) AML cells.
    Torgersen ML; Engedal N; Bøe SO; Hokland P; Simonsen A
    Blood; 2013 Oct; 122(14):2467-76. PubMed ID: 23970379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia.
    El-Khoury V; Pierson S; Szwarcbart E; Brons NH; Roland O; Cherrier-De Wilde S; Plawny L; Van Dyck E; Berchem G
    Leukemia; 2014 Aug; 28(8):1636-46. PubMed ID: 24418989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of HDAC and topoisomerase inhibitors in small cell lung cancer.
    Gray J; Cubitt CL; Zhang S; Chiappori A
    Cancer Biol Ther; 2012 Jun; 13(8):614-22. PubMed ID: 22441819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Endocrine; 2016 Feb; 51(2):274-82. PubMed ID: 26219406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homoharringtonine and SAHA synergistically enhance apoptosis in human acute myeloid leukemia cells through upregulation of TRAIL and death receptors.
    Cao H; Cheng Y; You L; Qian J; Qian W
    Mol Med Rep; 2013 Jun; 7(6):1838-44. PubMed ID: 23620163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
    Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
    Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.
    Martin AP; Park MA; Mitchell C; Walker T; Rahmani M; Thorburn A; Häussinger D; Reinehr R; Grant S; Dent P
    Mol Pharmacol; 2009 Aug; 76(2):327-41. PubMed ID: 19483105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
    Zhou L; Chen S; Zhang Y; Kmieciak M; Leng Y; Li L; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Rahmani M; Povirk L; Chalasani S; Berger AJ; Dai Y; Grant S
    Blood; 2016 May; 127(18):2219-30. PubMed ID: 26851293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDAC inhibitor Vorinostat and BET inhibitor Plx51107 epigenetic agents' combined treatments exert a therapeutic approach upon acute myeloid leukemia cell model.
    Alcitepe İ; Salcin H; Karatekin İ; Kaymaz BT
    Med Oncol; 2022 Oct; 39(12):257. PubMed ID: 36224430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo.
    Qi W; Zhang W; Edwards H; Chu R; Madlambayan GJ; Taub JW; Wang Z; Wang Y; Li C; Lin H; Ge Y
    Cancer Biol Ther; 2015; 16(12):1784-93. PubMed ID: 26529495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells.
    Petruccelli LA; Dupéré-Richer D; Pettersson F; Retrouvey H; Skoulikas S; Miller WH
    PLoS One; 2011; 6(6):e20987. PubMed ID: 21695163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
    Fournel M; Bonfils C; Hou Y; Yan PT; Trachy-Bourget MC; Kalita A; Liu J; Lu AH; Zhou NZ; Robert MF; Gillespie J; Wang JJ; Ste-Croix H; Rahil J; Lefebvre S; Moradei O; Delorme D; Macleod AR; Besterman JM; Li Z
    Mol Cancer Ther; 2008 Apr; 7(4):759-68. PubMed ID: 18413790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a novel synergistic induction of cell death by Smac mimetic and HDAC inhibitors in acute myeloid leukemia cells.
    Steinwascher S; Nugues AL; Schoeneberger H; Fulda S
    Cancer Lett; 2015 Sep; 366(1):32-43. PubMed ID: 26028172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737.
    Wiegmans AP; Alsop AE; Bots M; Cluse LA; Williams SP; Banks KM; Ralli R; Scott CL; Frenzel A; Villunger A; Johnstone RW
    Cancer Res; 2011 May; 71(10):3603-15. PubMed ID: 21398407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy.
    Thomas S; Thurn KT; Biçaku E; Marchion DC; Münster PN
    Breast Cancer Res Treat; 2011 Nov; 130(2):437-47. PubMed ID: 21298336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.